Comparative Pharmacology
Head-to-head clinical analysis: DEMULEN 1 50 21 versus LO MALMOREDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMULEN 1 50 21 versus LO MALMOREDE.
DEMULEN 1/50-21 vs LO-MALMOREDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.
LO-MALMOREDE is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1) that acts as a GLP-1 receptor agonist. It enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety by activating GLP-1 receptors in the pancreas, gastrointestinal tract, and central nervous system.
1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.
Adults: 10 mg orally once daily, titrated to 20 mg once daily after 2 weeks if tolerated.
None Documented
None Documented
Ethinylestradiol: 13 ± 3 h (biphasic; terminal phase used for dosing interval). Clinical context: steady-state achieved after ~3 days; missed dose may reduce contraceptive efficacy if >36 h.
Terminal elimination half-life is approximately 4-6 hours; prolonged to 12-18 hours in moderate-to-severe renal impairment, requiring dose interval extension.
Renal (approx. 50% as metabolites, <1% unchanged), fecal (approx. 40%, largely as ethinylestradiol conjugates), biliary (minor, enterohepatic recirculation of ethinylestradiol)
Primarily renal (75-90% unchanged); renal clearance approximates GFR, with dose adjustment needed for CrCl <30 mL/min. Biliary/fecal excretion accounts for <10%.
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive